Altimmune Inc. disclosed top-line phase IIb results for pemvidutide, a peptide-based dual GLP-1/glucagon receptor agonist targeting metabolic dysfunction-associated steatohepatitis (MASH). The treatment met one primary endpoint of MASH resolution without worsened fibrosis but failed to show statistical significance in fibrosis improvement without aggravation of MASH. While the outcomes dampened investor enthusiasm with shares halving, the drug’s potential for inducing weight loss remains noted. These findings delineate the challenging landscape for developing effective therapies in fatty liver disease.